Which phase is focused on monitoring long-term safety after a drug has been marketed?

Which phase is focused on monitoring long-term safety after a drug has been marketed?

• A. Phase 1
• B. Phase 2
• C. Phase 3
• D. Phase 4

Answer: (D)

Phase 4 is the post-marketing phase focused on long-term safety after a drug is marketed. Once a drug reaches broad real-world use, it’s exposed to a much larger and more diverse group of people, often over longer periods. Rare adverse effects or those that only appear with long-term exposure, aging, or interactions with other medications may not show up in earlier trials. Phase 4 involves ongoing safety monitoring, spontaneous adverse event reporting, and sometimes dedicated long-term or real-world studies. This surveillance can lead to updated labeling, warnings, restricted use, or even withdrawal if new risks arise.

Phase 4 is the post-marketing phase focused on long-term safety after a drug is marketed. Once a drug reaches broad real-world use, it’s exposed to a much larger and more diverse group of people, often over longer periods. Rare adverse effects or those that only appear with long-term exposure, aging, or interactions with other medications may not show up in earlier trials. Phase 4 involves ongoing safety monitoring, spontaneous adverse event reporting, and sometimes dedicated long-term or real-world studies. This surveillance can lead to updated labeling, warnings, restricted use, or even withdrawal if new risks arise.